Circumventing pyroptosis via hyperactivation shapes superior immune responses of human type 2 dendritic cells compared to type 3 dendritic cells
European Journal of Immunology · 2023-09 · 53 (9)
DOI: 10.1002/eji.202250123 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, online erschienen am 14.03.2023. Verfasst von Lukas Hatscher und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, 9…. Hauptthemen laut MEDLINE: Pyroptosis, Inflammasomes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Exploiting inflammasome activation in dendritic cells (DCs) is a promising approach to fight cancer and to augment adjuvant‐induced immune responses. As inflammasome formation is typically accompanied by pyroptosis, hyperactivation—defined as inflammasome activation in the absence of pyroptosis—represents a mechanism of circumventing cell death of DCs while simultaneously benefitting from inflammasome signaling. We previously demonstrated a unique specialization for inflammasome responses and hyperactivation of human cDC2 among all human DC subsets. As recent investigations revealed heterogeneity among the human cDC2 population, we aimed to analyze whether the two recently identified cDC2 subpopulations DC2 and DC3 harbor similar or different inflammasome characteristics. Here, we report that both DC2 and DC3 are inflammasome competent. We show that DC3 generally induce stronger inflammasome responses, which are associated with higher levels of cell death. Although DC2 release lower levels of inflammasome‐dependent IL‐1β, they induce stronger CD4 + T cell responses than DC3, which are predominantly skewed toward a T H 1/T H 17 phenotype. Thus, mainly DC2 seem to be able to enter a state of hyperactivation, resulting in enhanced T cell stimulatory capacity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Dendritic Cell Biology, Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, 91052, Erlangen, Germany.
- Deutsches Zentrum Immuntherapie, 91054, Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg, 91054, Erlangen, Germany.
- Medical Immunology Campus Erlangen, 91054, Erlangen, Germany.
ORCID-Profile: Lukas Heger
Zitieren
APA
Hatscher, L., Kaszubowski, T., Amon, L., Dudziak, D., & Heger, L. (2023). Circumventing pyroptosis via hyperactivation shapes superior immune responses of human type 2 dendritic cells compared to type 3 dendritic cells. European Journal of Immunology, 53(9). https://doi.org/10.1002/eji.202250123
Vancouver
Hatscher L, Kaszubowski T, Amon L, Dudziak D, Heger L. Circumventing pyroptosis via hyperactivation shapes superior immune responses of human type 2 dendritic cells compared to type 3 dendritic cells. European Journal of Immunology. 2023;53(9). doi:10.1002/eji.202250123
BibTeX
@article{Hatscher2023,
author = {Hatscher, Lukas and Kaszubowski, Tomasz and Amon, Lukas and Dudziak, Diana and Heger, Lukas},
title = {Circumventing pyroptosis via hyperactivation shapes superior immune responses of human type 2 dendritic cells compared to type 3 dendritic cells},
journal = {European Journal of Immunology},
year = {2023},
volume = {53},
number = {9},
doi = {10.1002/eji.202250123}
}
EUVIMED